Targeted Therapies for Hepatocellular Carcinoma
TLDR
Identification of oncogenes that mediate tumor progression, and trials that monitor their products as biomarkers, might lead to personalized therapy; reagents that interfere with signaling pathways required for HCC progression might be used to treat selected populations, and thereby maximize the efficacy and cost benefit.About:
This article is published in Gastroenterology.The article was published on 2011-05-01 and is currently open access. It has received 402 citations till now. The article focuses on the topics: Sorafenib & Targeted therapy.read more
Citations
More filters
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Josep M. Llovet,Michel Ducreux,Riccardo Lencioni,Adrian M. Di Bisceglie,Jean-Francois J. DuFour,Tim F. Greten,Eric Raymond,Tania Roskams,Vincenzo Mazzaferro,Jordi Bruix,Massimo Colombo,Andrew X. Zhu +11 more
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
Journal ArticleDOI
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro,Carlos Gomez-Martin,Manuel de la Mata,Mercedes Iñarrairaegui,Elena Garralda,Pilar Barrera,Jose I Riezu-Boj,Esther Larrea,Carlos Alfaro,Pablo Sarobe,Juan José Lasarte,Jose Luis Perez-Gracia,Ignacio Melero,Ignacio Melero,Jesús Prieto,Jesús Prieto +15 more
TL;DR: Tremelimumab safety profile and antitumor and antiviral activity, in patients with advanced HCC developed on HCV-induced liver cirrhosis, support further investigation.
Journal ArticleDOI
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
TL;DR: In this paper, a review outlines pathogenic mechanisms that seem to be common to both hepatitis B virus and hepatitis C virus and suggest innovative approaches to the prevention and treatment of HCC.
Journal ArticleDOI
Mechanisms of HBV-induced hepatocellular carcinoma
TL;DR: HBV-related HCCs may arise on non-cirrhotic livers, further supporting the notion that HBV plays a direct role in liver transformation by triggering both common and etiology specific oncogenic pathways in addition to stimulating the host immune response and driving liver chronic necro-inflammation.
References
More filters
Journal ArticleDOI
Molecular Targeted Therapies in Hepatocellular Carcinoma
Shinji Tanaka,Shigeki Arii +1 more
TL;DR: Molecular targeted therapy with a focus on angiogenesis, growth signals, and mitotic abnormalities, as well as the promising concepts of "cancer stemness" and "synthetic lethality" for the strategy of targeted therapy are summarized.
Journal ArticleDOI
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.
Eduardo Schiffer,Chantal Housset,Wulfran Cacheux,Dominique Wendum,Christèle Desbois-Mouthon,Colette Rey,François Clergue,Raoul Poupon,Véronique Barbu,Olivier Rosmorduc +9 more
TL;DR: The blockade of EGFR activity by gefitinib has an antitumoral effect on the development of HCC in DEN‐exposed rats, suggesting that it may provide benefit for the chemoprevention of H CC.
Journal ArticleDOI
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
Melanie B. Thomas,Romil Chadha,Katrina Y. Glover,Xuemei Wang,Jeffrey S. Morris,Thomas Brown,Asif Rashid,Janet Dancey,James L. Abbruzzese +8 more
TL;DR: The proportion of hepatocellular carcinoma patients treated with erlotinib who were alive and progression-free (PFS) at 16 weeks of continuous treatment was determined.
Journal ArticleDOI
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.
Yujin Hoshida,Sara Toffanin,Anja Lachenmayer,Augusto Villanueva,Beatriz Minguez,Josep M. Llovet,Josep M. Llovet +6 more
TL;DR: A new class of genomic information, microRNA dysregulation and epigenetic alterations, will provide insight for more precise understanding of disease mechanism and expand the opportunity of biomarker/therapeutic target discovery that will eventually enable personalized management of HCC.
Journal ArticleDOI
Systematic Overview of Cost-Utility Assessments in Oncology
Craig C. Earle,Richard H. Chapman,C.S. Baker,Chaim M. Bell,Patricia W. Stone,Eileen A. Sandberg,Peter J. Neumann +6 more
TL;DR: The cost-utility literature in oncology is not large but is rapidly expanding, and there remains much room for improvement in the methodological rigor with which utilities are measured.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more